SXI Life Sciences
|
6 778,00
|
101,43
|
1,52%
|
Analysen zu SXI Life Sciences-Werten
| 16.01.24 | Novartis Buy | Jefferies & Company Inc. | |
| 16.01.24 | Roche Hold | Jefferies & Company Inc. | |
| 15.01.24 | Roche Neutral | UBS AG | |
| 15.01.24 | Novartis Buy | UBS AG | |
| 15.01.24 | Roche Underweight | JP Morgan Chase & Co. | |
| 11.01.24 | Roche Underweight | JP Morgan Chase & Co. | |
| 09.01.24 | Roche Equal Weight | Barclays Capital | |
| 09.01.24 | Novartis Neutral | JP Morgan Chase & Co. | |
| 08.01.24 | Novartis Neutral | JP Morgan Chase & Co. | |
| 08.01.24 | Novartis Neutral | UBS AG | |
| 05.01.24 | Novartis Buy | Deutsche Bank AG | |
| 03.01.24 | Novartis Neutral | JP Morgan Chase & Co. | |
| 03.01.24 | Novartis Buy | Jefferies & Company Inc. | |
| 03.01.24 | Roche Hold | Jefferies & Company Inc. | |
| 02.01.24 | Roche Underweight | JP Morgan Chase & Co. | |
| 21.12.23 | Novartis Underweight | Barclays Capital | |
| 19.12.23 | Novartis Buy | Deutsche Bank AG | |
| 18.12.23 | Roche Sell | Deutsche Bank AG | |
| 11.12.23 | Roche Underweight | JP Morgan Chase & Co. | |
| 06.12.23 | Roche Sell | Deutsche Bank AG | |
| 05.12.23 | Roche Sell | Deutsche Bank AG | |
| 05.12.23 | Novartis Neutral | JP Morgan Chase & Co. | |
| 05.12.23 | Roche Underweight | JP Morgan Chase & Co. | |
| 04.12.23 | Roche Neutral | UBS AG | |
| 04.12.23 | Roche Hold | Jefferies & Company Inc. | |
| 01.12.23 | Roche Sell | Deutsche Bank AG | |
| 30.11.23 | Roche Underweight | JP Morgan Chase & Co. | |
| 30.11.23 | Novartis Buy | Deutsche Bank AG | |
| 29.11.23 | Novartis Underweight | Barclays Capital | |
| 28.11.23 | Novartis Neutral | UBS AG | |
| 28.11.23 | Novartis Buy | Jefferies & Company Inc. | |
| 27.11.23 | Novartis Buy | Deutsche Bank AG | |
| 01.11.23 | Roche Sell | Deutsche Bank AG | |
| 31.10.23 | Roche Underweight | JP Morgan Chase & Co. | |
| 30.10.23 | Roche Equal Weight | Barclays Capital | |
| 26.10.23 | Novartis Buy | Deutsche Bank AG | |
| 24.10.23 | Novartis Neutral | UBS AG | |
| 24.10.23 | Novartis Buy | Jefferies & Company Inc. | |
| 23.10.23 | Novartis Underweight | Barclays Capital | |
| 23.10.23 | Roche Neutral | UBS AG |
HOT STOCKS DER LETZTEN 3 TAGE
| Roche | 5 |
Analysen zu Aktien folgender Indizes
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.